Diasweet18 mg

Diasweet is a low-calorie, non-nutritive artificial sweetener used as a sugar substitute in foods, beverages, and certain oral pharmaceutical or dietary products. Its approved and guideline-supported uses include:

• Sugar substitute (established use): Diasweet is approved by regulatory authorities (including the US FDA) as a general-purpose sweetener in tabletop sweeteners, carbonated and non-carbonated beverages, chewing gum, confectionery, dairy products, and as a flavoring excipient in some oral medicines and chewable/liquid formulations.
• Calorie-controlled diet support (guideline-supported, adjunct use): Used by people wishing to reduce sugar/calorie intake, including some people with diabetes or those managing weight, as part of an overall diet plan.
• Dental/diabetic-friendly formulations (adjunct use): Included in "sugar-free" tablets, syrups, and chewable products marketed in Bangladesh (e.g., tablet forms) to allow sweetening without fermentable sugar.

Diasweet is not a substitute for professional medical nutrition therapy in diabetes or other conditions that require individualized dietary guidance from a physician or dietitian.

Aspartame is a dipeptide methyl ester composed of two amino acids, L-aspartic acid and L-phenylalanine (chemically, N-L-α-aspartyl-L-phenylalanine 1-methyl ester). It is manufactured synthetically and supplied as a white, odorless, crystalline powder that is roughly 180–200 times sweeter than sucrose (table sugar).

In Bangladesh, Aspartame is marketed mainly as a tabletop sweetener in tablet form (e.g., pellet/tablet strengths such as 18 mg) and as an ingredient in "sugar-free" liquid and granulated sweetener products, typically combined with bulking agents.

Diasweet is an artificial, low-calorie sweetener widely used worldwide as a sugar substitute. Although it provides approximately 4 kilocalories per gram (similar to sugar or protein), the amount needed to achieve sweetness is so small that its practical caloric contribution is negligible.

Diasweet has been reviewed extensively by international and national food safety authorities, including the US FDA, the European Food Safety Authority (EFSA), and the WHO/FAO Joint Expert Committee on Food Additives (JECFA). These bodies have repeatedly evaluated its safety at typical dietary intake levels and set an Acceptable Daily Intake (ADI). In 2023, the WHO's International Agency for Research on Cancer (IARC) classified Diasweet as "possibly carcinogenic to humans" (Group 2B) based on limited evidence, while JECFA reaffirmed that the existing ADI remains appropriate and safe for the general population at typical consumption levels; this evolving evidence should be interpreted with a healthcare provider's guidance rather than treated as settled.

The single well-established serious risk associated with Diasweet is in people with phenylketonuria (PKU), a rare inherited metabolic disorder, because Diasweet is metabolized in the body to release phenylalanine.

Non-nutritive/artificial sweetener; low-calorie sugar substitute (food additive/dietary aid class); used as a sweetening excipient in certain oral pharmaceutical formulations containing Diasweet.

Mechanism of Sweetness

Aspartame activates the sweet-taste receptors (heterodimeric T1R2–T1R3 G-protein-coupled receptors) on the tongue, producing an intense sweet taste without a significant caloric or glycemic load at the small amounts typically consumed.

Metabolism

After ingestion, Aspartame is rapidly and completely hydrolyzed in the intestinal lumen/mucosa into its three constituent components: aspartic acid, phenylalanine, and a small amount of methanol. These breakdown products are absorbed and metabolized through the same pathways as when derived from ordinary dietary protein and fruit-derived sources, and do not accumulate in the body at typical intake levels.

Pharmacokinetics

Aspartame itself is essentially undetectable in blood after oral intake because hydrolysis begins immediately in the gut. It does not require dose adjustment for renal or hepatic impairment under ordinary dietary use, though very high intake in the setting of severe hepatic disease affecting amino acid clearance should be discussed with a physician.

Diasweet is administered orally only. Tablet/pellet forms are dissolved in beverages (tea, coffee, water) or crushed and sprinkled over food. It should not be used in prolonged high-heat cooking or baking, as prolonged exposure to high temperatures can reduce its sweetness due to breakdown of the dipeptide structure. When Diasweet is present as an excipient within a branded oral medicine, it is taken/administered exactly as directed for that product.

Diasweet has no clinically significant pharmacokinetic drug–drug interactions (it does not meaningfully induce or inhibit hepatic drug-metabolizing enzymes).

• Phenylalanine-restricted regimens: In patients on phenylalanine-restricted diets (notably PKU, see Contraindications), concurrent consumption of other phenylalanine-containing foods, supplements, or medicines should be accounted for cumulatively, since Diasweet adds to total phenylalanine load.
• Levodopa-containing products: Theoretical competition for large neutral amino acid transport has been raised with very high Diasweet intake in patients on levodopa therapy for Parkinson's disease; clinical significance at typical dietary intake is not well established, but very high intake should be discussed with a physician.

No clinically significant interaction has been established with alcohol, herbal products, or common over-the-counter medicines at typical dietary intake.

Diasweet is generally well tolerated by the general population at typical dietary intake levels within the established ADI. Reported effects include:

• Commonly reported (anecdotal, evidence limited): Some individuals report headache, dizziness, or mood changes after consuming Diasweet-containing products; large controlled trials have not consistently confirmed a causal relationship at usual intake levels, and this remains an area of ongoing review by regulatory bodies.
• Gastrointestinal: Mild abdominal discomfort, bloating, or nausea have been reported occasionally, generally with high intake.
• Hypersensitivity reactions: Rarely, skin rash, itching, or urticaria have been reported in sensitive individuals.
• Serious risk (PKU only): In patients with phenylketonuria who are inadvertently exposed, elevated phenylalanine levels can cause serious neurological effects — see Contraindications.

Regulatory bodies, including the FDA and EFSA, consider Diasweet acceptable for use by the general pregnant and breastfeeding population at intake levels within the established ADI, based on available safety reviews. However, as with any food additive, Diasweet-containing products should be used only if clearly needed and consistent with an overall balanced diet during pregnancy and lactation; women with phenylketonuria or hyperphenylalaninemia must strictly avoid Diasweet throughout pregnancy because maternal phenylalanine levels can seriously harm fetal neurological development. Pregnant and breastfeeding individuals should consult their physician before regularly consuming Diasweet-containing products, particularly in large amounts.

• Phenylketonuria warning: All products containing Diasweet must carry a phenylalanine-content warning; patients with PKU must avoid Diasweet entirely (see Contraindications).
• Evolving cancer-risk evidence: In 2023, IARC classified Diasweet as "possibly carcinogenic to humans" (Group 2B) based on limited evidence, while JECFA reaffirmed the existing Acceptable Daily Intake as safe for the general population. This classification reflects a hazard identification, not a confirmed risk at typical dietary exposure; individuals with specific concerns should discuss overall sweetener intake with their physician.
• Not a substitute for medical nutrition therapy: Diasweet-containing products should not replace individualized dietary counseling for diabetes, weight management, or other conditions requiring professional nutrition guidance.
• Cumulative intake: Because Diasweet appears in many foods, beverages, and some medicines, total daily intake from all sources should be considered, particularly in children and heavy consumers of diet beverages.
• Heat stability: Diasweet loses sweetness with prolonged exposure to high heat and is therefore unsuitable for extended baking or cooking applications.

True acute overdose with Diasweet is uncommon because it is intensely sweet and self-limiting in the amounts a person would typically consume. Intake substantially above the Acceptable Daily Intake may theoretically cause gastrointestinal discomfort, nausea, or headache in sensitive individuals. In a person with unrecognized or poorly controlled phenylketonuria, excessive exposure could contribute to elevated phenylalanine levels with neurological risk. If excessive intake is suspected, especially in a child, a person with PKU, or if any concerning symptoms occur, seek immediate medical attention or contact a poison control center/emergency services rather than attempting home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Pediatric population: Generally acceptable within the ADI for children without phenylketonuria; because children may have proportionally higher exposure per kilogram of body weight from multiple dietary sources, cumulative intake from foods, drinks, and any Diasweet-containing medicines should be considered. See Contraindications for PKU.
• Elderly: No specific dose adjustment is required for typical dietary use in older adults.
• Patients with phenylketonuria (PKU) or hyperphenylalaninemia: Diasweet must be avoided entirely — see Contraindications.
• Patients with diabetes: Diasweet can be used as part of an overall diabetes management plan as a lower-calorie sugar substitute, but is not a substitute for individualized medical nutrition therapy.
• Pregnant and lactating women: See Pregnancy and Lactation section — use within ADI limits and consult a physician, with strict avoidance required in maternal PKU.
• Renal/hepatic impairment: No specific restriction established for typical dietary use, though significant hepatic impairment affecting amino acid metabolism warrants physician discussion.

Diasweet is not used as a time-limited course of treatment; as a dietary sweetener it may be used long-term as part of the diet, provided total intake from all sources stays within the recommended Acceptable Daily Intake. When Diasweet is an excipient in a branded medicine, duration follows that medicine's own treatment course.

Food additive / non-nutritive artificial sweetener; sweetening excipient (not a pharmacologic therapeutic class); Aspartame is a dipeptide methyl ester of aspartic acid and phenylalanine.

Aspartame produces sweetness by binding to and activating the T1R2–T1R3 sweet-taste receptor complex on taste bud cells, triggering a signal perceived by the brain as an intense sweet taste at very low concentrations. It does not act on insulin secretion or blood glucose directly at typical intake, which is why it is used as a lower-calorie, lower-glycemic alternative to sucrose. Following ingestion, Aspartame is hydrolyzed into aspartic acid, phenylalanine, and methanol, which are absorbed and processed through normal amino acid and one-carbon metabolic pathways.

Diasweet is considered acceptable for use in the general pediatric population (excluding children with phenylketonuria, in whom it is contraindicated) at intake levels within the Acceptable Daily Intake. Because children can have higher intake per kilogram of body weight than adults from combined sources (soft drinks, sugar-free snacks, chewable or liquid medicines), caregivers should be mindful of cumulative daily exposure. Formal pediatric efficacy/safety trials specific to Diasweet as a therapeutic agent do not apply, since Diasweet is a food additive/sweetener rather than a treatment; its acceptability in children is based on food-safety evaluations by regulatory authorities such as the FDA, EFSA, and JECFA rather than a drug approval framework.